September 03, 2026 — RNews

#esophageal — Thursday, September 03, 2026 (1 items)

hot top new

← prev day next day →

0

First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306). (nature.com)

Yoon HH … Xu J Nature Communications 2026-09-03

#cancer #clinical trial #immunotherapy #chemotherapy #esophageal